Mabtas N 100 mg Injection
$83.74
$65.31
Mabtas N 100 mg Injection is a powerful monoclonal antibody designed to target and treat various immune system-related disorders, particularly certain types of cancers such as non-Hodgkin's lymphoma and chronic lymphocytic leukemia. By specifically binding to cancer cells, this innovative medication helps to inhibit their growth and promotes the body's immune response to eliminate these abnormal cells. It is essential to be aware that Mabtas N may cause side effects, including infusion reactions and increased risk of infections, so patients should be closely monitored during treatment. Additionally, it is crucial for individuals with a history of hypersensitivity to any components of the drug to discuss this with their healthcare provider prior to administration. This injection not only plays a significant role in managing these malignancies but also serves as a vital option for those seeking advanced therapeutic interventions. As with any medical treatment, consulting with a healthcare professional is key to understanding the benefits and risks associated with Mabtas N. Overall, this medication represents a critical advancement in cancer therapy, providing hope for many patients battling these challenging conditions.
Quantity
Active Pharmaceutical Ingredient
Uses
• Mabtas n 100 mg injection is commonly used in the treatment of non-Hodgkin lymphoma (NHL). This condition involves the uncontrolled growth of lymphocytes, a type of white blood cell. The injection helps to target and destroy these cancerous cells, potentially leading to improved patient outcomes. Healthcare providers may consider Mabtas n 100 mg injection as part of a comprehensive treatment plan for NHL.
• Patients with rheumatoid arthritis can benefit from Mabtas n 100 mg injection as it aids in managing the symptoms of this chronic autoimmune condition. By modulating the immune response, the injection helps reduce inflammation and joint damage. This is particularly important for maintaining mobility and quality of life in affected individuals. Mabtas n 100 mg injection may be used when other therapies are insufficient.
• Mabtas n 100 mg injection is also indicated for the treatment of chronic lymphocytic leukaemia, a type of blood cancer characterized by the accumulation of abnormal lymphocytes. The injection works by specifically targeting these cells, helping to control the disease progression. This targeted approach can lead to better management of the condition. Patients undergoing treatment may experience a significant reduction in disease-related symptoms with Mabtas n 100 mg injection.
• In cases of granulomatosis with polyangiitis and microscopic polyangiitis, Mabtas n 100 mg injection plays a crucial role in managing these rare autoimmune vasculitis disorders. It helps to alleviate symptoms by suppressing the immune system's abnormal response. This can lead to decreased inflammation and improved organ function. Mabtas n 100 mg injection is often utilized in conjunction with other therapies for optimal patient care.
Benefits
Non-Hodgkin lymphoma (NHL): Non-Hodgkin's lymphoma is a form of cancer that affects the white blood cells in the body. These cells are responsible for preventing infections. Mabtas N 100 mg Injection has been demonstrated to reduce the immune response and relieve pain and inflammation. It also can kill cancer cells and prevent their further growth. To prevent the spread of infection, it is advisable to avoid crowds and to wash your hands frequently. It is recommended that patients consume an adequate quantity of fluids unless otherwise advised by their physician.
Rheumatoid arthritis: Mabtas N 100 mg is an immunosuppressant that is used to treat rheumatoid arthritis. It is administered in a dose and frequency that is tailored to the patient's condition. This is determined by the physician. It is crucial to adhere to the physician's instructions and to promptly report any adverse effects, including fever, chills, or other symptoms, to the physician.
Blood cancer (chronic lymphocytic leukemia): Leukemia, also known as blood cancer, is a malignant neoplasm of the hematopoietic tissues that impairs the body's ability to combat infection. Mabtas N 100 Injection is a chemotherapeutic agent that kills or inhibits the proliferation of malignant cells and is effective in the treatment of leukemia. However, it is important to discuss the potential side effects and benefits of this medication with a qualified healthcare professional. It is also essential to inform your doctor of any adverse effects that may arise during treatment.
Granulomatosis with polyangiitis: Granulomatosis with polyangiitis (GPA) is a condition that causes inflammation of the blood vessels of the ears, nose, throat, lungs, and kidneys. In this condition, the blood flow to these areas may be reduced, which can lead to their damage. Mabtas N 100 mg Injection is an effective treatment that helps reduce inflammation, pain, and swelling and prevents further damage. This improves the quality of life of those affected by GPA.
Microscopic polyangiitis: Microscopic polyangiitis is an autoimmune disease that affects the small blood vessels and may be caused by an imbalance in the immune system. Mabtas N 100 mg Injection reduces the immune response and improves inflammation. This helps to heal the condition and to alleviate discomfort.
Side Effects
Mabtas N 100 mg Injection can cause various adverse effects that can differ from one person to another. Some of the adverse effects of the drug are listed below.
Most Common Side Effects
• Low Immunity
• Nausea
• Tinnitus
• Muscle Pain and Stiffness
• Face Swelling
• Low Blood Count of White Blood Cells and Red Blood Cells
• Increase in Glucose Levels in Blood
• Headache
Common Side Effects
• Skin Reactions
• Heart Problems
• Infections
• Allergies
How To Use
The administration of Mabtas N 100 Injection is typically conducted by a medical professional, such as a doctor or nurse, in a medical facility, such as a hospital or clinic. It is not advisable to administer the product independently, and it is important to adhere to the instructions provided by a qualified healthcare professional.
Safety Advice
• Alcohol: Caution should be exercised when drinking alcohol with Mabtas N 100 mg. Please consult your doctor.
• Kidney: Mabtas N 100 mg Injection is likely to be safe in patients with kidney disease. The limited data available suggest that dose adjustment of Vortuxi Solution for Infusion may not be necessary for these patients. Please consult your doctor.
• Breastfeeding: Mabtas N 100 mg Injection is likely to be safe to use while breastfeeding, and limited human statistics support that the drug now no longer poses a good risk to the baby.
• Liver: Mabtas N 100 mg Injection is not recommended in patients with active liver disease or those who have had viral hepatitis. Please consult your doctor.
• Pregnancy: Mabtas N 100 mg Injection may not be safe for use during pregnancy. Although there is limited human research, animal research has shown dangerous effects on the growing baby. Your doctor will weigh up the benefits and potential risks before prescribing it to you. Please consult your doctor.
• Driving: It is not known whether Mabtas N 100 mg affects your ability to drive. Do not drive if you experience symptoms that affect your ability to concentrate and react.